Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Degludec/Liraglutide (DUAL III) in T2D
NCT01676116Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2012
- Primary completion
- Mar 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 3 trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Aug 2012; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01676116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01676116.